Logo

SNTI

Senti Biosciences, Inc.

SNTI

Senti Biosciences, Inc. • NASDAQ
$2.23 ▲ 5.69% (+0.12)
Market Cap $58.62 M
52w High $16.94
52w Low $1.26
Dividend Yield 0%
P/E -0.78
Volume 46.19K
Outstanding Shares 26.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $16.044M ▲ $-18.126M ▼ 0% $-0.69 ▼ $-17.222M ▼
Q2-2025 $0 $15.322M ▼ $-14.733M ▼ 0% $-0.56 ▲ $-13.257M ▲
Q1-2025 $0 $16.397M ▲ $-14.112M ▼ 0% $-3.07 ▼ $-14.929M ▼
Q4-2024 $0 $14.708M ▼ $-610K ▲ 0% $-0.13 ▲ $848.999K ▲
Q3-2024 $0 $15.215M $-28.866M 0% $-6.31 $-13.438M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.243M ▼ $52.685M ▼ $44.564M ▲ $8.121M ▼
Q2-2025 $21.576M ▼ $68.54M ▼ $43.888M ▼ $24.652M ▼
Q1-2025 $33.802M ▼ $82.778M ▼ $44.919M ▼ $37.859M ▲
Q4-2024 $48.277M ▲ $97.841M ▲ $72.192M ▲ $25.649M ▲
Q3-2024 $10.479M $57.721M $41.727M $15.994M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-18.126M ▼ $-9.446M ▲ $0 ▲ $124K ▼ $-9.333M ▲ $-9.446M ▲
Q2-2025 $-14.733M ▼ $-13.073M ▲ $-184K ▼ $1.011M ▲ $-12.226M ▲ $-13.269M ▲
Q1-2025 $-14.112M ▼ $-14.05M ▼ $0 ▲ $-414K ▼ $-14.475M ▼ $-14.05M ▼
Q4-2024 $-610K ▲ $-13.504M ▼ $-11K ▼ $51.29M ▲ $37.798M ▲ $-13.515M ▼
Q3-2024 $-28.866M $-7.866M $60K $2.44M $-5.381M $-7.866M

Revenue by Products

Product Q1-2023Q2-2023
License
License
 $0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Senti has been in pure R&D mode: it has essentially no product or licensing revenue yet and has reported steady losses each year. Spending is dominated by research and operating costs, which is normal for an early-stage biotech but means the company is far from breakeven. Losses have been sizable on a per-share basis, reflecting both high R&D intensity and a small revenue base. The overall pattern is a business still firmly in the “investment phase,” with future outcomes tied to clinical and partnership milestones rather than current earnings power.

Balance Sheet

Balance Sheet The balance sheet is small and relatively simple. The company holds a modest cash balance and a limited amount of total assets, with some debt but not an excessive level by biotech standards. Equity moved from negative to positive but has shrunk in recent years, showing that cumulative losses are eroding the capital base. The recent reverse stock split is more about meeting listing standards and does not improve the underlying financial strength. Overall, the balance sheet gives the company some runway, but not a long one if losses continue at the current pace without new funding.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating losses and ongoing R&D activity. Free cash flow has been meaningfully negative every year, with only light capital spending. This pattern underscores that Senti relies on external financing—equity, debt, or partnership payments—to fund its programs. Without substantial new cash inflows, either from deals or capital markets, the company’s ability to sustain its current level of R&D spending would be constrained over time.

Competitive Edge

Competitive Edge Scientifically, Senti is positioned in an attractive but crowded area: engineered cell therapies for cancer. Its differentiation comes from its gene circuit platform and logic-gated CAR‑NK designs, which aim to make therapies both smarter and safer than first‑generation cell therapies. Early clinical signals in blood cancers and partnerships with larger pharma players add credibility. However, Senti faces competition from many better-funded companies in CAR‑T, NK, and other cell and gene therapy modalities, and it must still prove that its approach delivers clearly superior outcomes and can be manufactured reliably at scale.

Innovation and R&D

Innovation and R&D Innovation is the core of Senti’s story. The company is pushing a synthetic biology approach where cell therapies behave like programmable systems, using logic gates and controlled payload release. Lead programs in blood cancers and liver cancer showcase this concept, and the use of off‑the‑shelf NK cells aims to improve safety and convenience versus patient‑specific approaches. R&D is also leveraged through a “design‑build‑test‑learn” engine and several strategic collaborations that extend the technology into gene therapy and regenerative medicine. The opportunity is significant, but the programs remain early-stage, so scientific and clinical risk is still high.

Summary

Senti Biosciences is a high‑risk, high‑uncertainty early biotech with no current revenue, ongoing losses, and a limited but workable cash cushion. Its value proposition rests almost entirely on the potential of its gene circuit platform and logic‑gated CAR‑NK therapies, supported by promising early data and notable partnerships. Financially, the company is in an investment-heavy phase and dependent on external funding, a common but important risk factor. If its clinical programs validate the technology and partnerships deepen, the upside to the business could be substantial; if they falter, the small balance sheet and persistent cash burn leave little margin for error.

NEWS

November 13, 2025 · 4:30 PM UTC

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Read more

November 3, 2025 · 9:05 AM UTC

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

Read more

October 16, 2025 · 9:05 AM UTC

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

Read more

October 6, 2025 · 9:05 AM UTC

Senti Bio to Present at BioJapan

Read more

September 18, 2025 · 9:15 AM UTC

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Read more